The antimicrobial natural product chuangxinmycin and Some synthetic analogues are potent and selective inhibitors of bacterial tryptophanyl tRNA synthetase

GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK.
Bioorganic & Medicinal Chemistry Letters (Impact Factor: 2.42). 12/2002; 12(21):3171-4. DOI: 10.1016/S0960-894X(02)00604-2
Source: PubMed


The antimicrobial natural product chuangxinmycin has been found to be a potent and selective inhibitor of bacterial tryptophanyl tRNA synthetase (WRS). A number of analogues have been synthesised. The interaction with WRS appears to be highly constrained, as only sterically smaller analogues afforded significant inhibition. The only analogue to show inhibition comparable to chuangxinmycin also had antibacterial activity. WRS inhibition may contribute to the antibacterial action of chuangxinmycin.

Download full-text


Available from: Murray Brown, Feb 03, 2015
45 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aminoacyl-tRNA synthetases (ARSs) are enzymes that translate the genetic code by adding amino acids to their cognate transfer RNAs (tRNA). Aminoacylated tRNAs can then be used by the ribosome to decode mRNA. The essential role of ARSs was established in the 1960s, during the golden era of molecular biology that led to the discovery of the genetic code. The canonical role of these enzymes is now described in all textbooks. Remarkably, however, interest in ARS function continues to grow as new and unexpected functions are discovered for these enzymes, for tRNA, and for RNA in general. This article describes current progress in the field of ARS research, summarizes current thinking about the evolution of ARSs, introduces the readers to the many facets of cellular biology in which ARSs play an important role, and discusses the biotechnological applications derived from these studies.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The palladium-catalyzed reaction of sulfinic acid salts with a wide variety of aryl and vinyl halides or triflates provides unsymmetrical diaryl sulfones and aryl vinyl sulfones in good to excellent yields. The reaction is strongly influenced by the presence of nBu4NCl, and the use of Xantphos, a rigid bidentate ligand with a wide natural bite angle, was found to be crucial for the success of the reaction. With neutral, electron-rich, and electron-poor aryl iodides best results were obtained by using Pd2(dba)3, Xantphos, Cs2CO3, and nBu4NCl, in toluene at 80 degrees C. Two general procedures were employed with aryl bromides and triflates: sodium p-toluenesulfinate, Pd2(dba)3, Xantphos, Cs2CO3, 120 degrees C, in toluene with nBu4NCl (procedure A: neutral, electron-rich, and slightly electron-poor aryl bromides or triflates) and without nBu4NCl (procedure B: electron-poor aryl bromides or triflates). With vinyl triflates best results were obtained at 60 degrees C omitting nBu4NCl.
    The Journal of Organic Chemistry 09/2004; 69(17):5608-14. DOI:10.1021/jo0493469 · 4.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gary Woodnutt – Diversa Corp., San Diego, CA, USA The explosion in the bacterial genomics area in the past decade has been remarkable, but there appears to have been little reward for all of this effort as judged by the relative lack of new antibacterial agents entering development. Chan et al. review these developments and suggest that, as far as target identification is concerned, the use of genomics has provided us with a wealth of potentially attractive opportunities, and failure to consolidate on these reflect on other deficits/difficulties in the antibacterial drug discovery process. Furthermore, the knowledge gained during this period has allowed considerable advances in genetic tools that can assist in tracking structure–activity relationships in the whole cell, and should enable the dissection of compound mode of action. In addition, these advances have been pivotal in understanding why certain promising candidates are less viable. Thus, the bacterial genomics era is far from being over and might actually have just begun to be applied appropriately.
    Drug Discovery Today Therapeutic Strategies 12/2004; 1(4):519-527. DOI:10.1016/j.ddstr.2004.11.003
Show more